(PDF) Discovery and Characterization of a Novel Potent Type

Discovery and Characterization of a Novel Potent Type II Native and Mutant BCR-ABL Inhibitor (CHMFL-074) for Chronic Myeloid Leukemia (CML)

Oncotarget - United States

doi 10.18632/oncotarget.10037

Full Text

Abstract

Available in full text

Categories

Date

June 14, 2016

Authors

Publisher

Impact Journals, LLC

Related search

CT-721, a Potent BCR-Abl Inhibitor, Exhibits Excellent in Vitro and in Vivo Efficacy in the Treatment of Chronic Myeloid Leukemia

Journal of Cancer

English

Detection of BCR-ABL Transcripts in Chronic Myeloid Leukemia (CML) Using a ‘Real Time’ Quantitative RT-PCR Assay

Cancer Research

English

Differential Genomics and Transcriptomics Between Tyrosine Kinase Inhibitor-Sensitive and -Resistant BCR-ABL-dependent Chronic Myeloid Leukemia

English

A Type-Ii Kinase Inhibitor Capable of Inhibiting the T315I “Gatekeeper” Mutant of BCR-Abl

Journal of Medicinal Chemistry

Molecular Medicine

English

The ABL Switch Control Inhibitor DCC-2036 Is Active Against the Chronic Myeloid Leukemia Mutant BCR-ABLT315I and Exhibits a Narrow Resistance Profile

Cancer Research

Cancer Research

English

Concamitant Expression of the Rare E1/A3 and B2/A3 Types of BCR/ABL Transcript in a Chronic Myeloid Leukemia (CML) Patient

Cancer Research

English

Acute Myeloid Leukemia With BCR/ABL Fusion Chimera

Indian Journal of Hematology and Blood Transfusion

English

Management of Chronic Myeloid Leukemia With BCR/ABL Inhibitors: Current Status and Future Perspectives

Clinical Medicine Insights: Therapeutics

Pharmaceutical Science

English

Adoptive Immunotherapy of BCR-ABL-induced Chronic Myeloid Leukemia-Like Myeloproliferative Disease in a Murine Model

English